We have previously shown that transient receptor potential vanilloid 4 (TRPV4) is downregulated in TEC, and that pharmacological activation of TRPV4 channels normalizes the tumor vasculature and improves cancer therapy (Adapala et al., 2016). The gene discussed is TRPV4; the disease is neoplasm.